PARKINSON KASALLIKDA KOGNITIV BUZISHLARNI RIVOJLANISHIDA NEYROTROFIK OMILLARNING TA’SIRI
##article.subject##:
demensiya, Parkinson kasalligi, MMP-9, NGF, IL-1, IL-6##article.abstract##
Maqolada neyrotrofik omillarni tahlil qilish va ularning Parkinson kasalligi bilan og'rigan bemorlarda kognitiv buzilish va demensiya rivojlanish xavfiga ta'siri haqida ma'lumotlar keltirilgan. Matrix metalloproteyinaza-9 va nerv o'sish omili va interleykin profilining qiyosiy bahosi berilgan va ularni diagnostika algoritmlariga kiritishning prognostik qiymati baholanadi.
Библиографические ссылки
Aarsland D., Beyer M.K., Kurz M.W. Dementia in Parkinson's disease. Curr. Opin. Neurol. 2018;21(6):676–682.
Svenningsson P., Westman E., Ballard C., Aarsland D. Cognitive impairment in patients with Parkinson's disease. Lancet Neurol. 2015;11(8):697–707.
Chahine L.M., Xie S.X., Simuni T. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behaviour disorder. Parkinsonism Relat Disord. 2016;27:102–106.
Zhang W., Wang T., Pei Z. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2015;19(6):533–542.
Bruno M.A., Cuello A.C. Activity-dependent release of precursor nerve growth factor and its maturation in CNS. Proc. Natl. Acad. Sci. USA. 2016;103(17):6735–6740.
Coughlin D.G., Hurtig H.I., Irwin D.J. Pathological influences on clinical heterogeneity in Lewy body diseases. Mov. Disord. 2020;35(1):5– 19.
Khaydarova D.K., Mansurova N.A. Analysis of Motor Complications in Parkinson’s Disease Phenotypes. Journal of Advances in Medicine and Medical Research. 25(5): 1-7, 2018;
Hansson O., Hall S., Ohrfelt A., et al. Levels of CSF α-synuclein oligomers in Parkinson's disease dementia. Alzheimers Res Ther. 2014;6(3):25.
Cheng B., Mattson M.P. NGF protects neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron. 2021;7(6):1031– 1041.
